Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P43632

UPID:
KI2S4_HUMAN

ALTERNATIVE NAMES:
CD158 antigen-like family member I; Natural killer-associated transcript 8; P58 natural killer cell receptor clones CL-39/CL-17

ALTERNATIVE UPACC:
P43632; Q6H2G7

BACKGROUND:
The protein KIR2DS4, also known as CD158 antigen-like family member I, Natural killer-associated transcript 8, and P58 natural killer cell receptor clones CL-39/CL-17, is a critical receptor on NK cells for HLA-C alleles. It is unique in that it does not inhibit NK cell activity, suggesting a distinct role in the immune surveillance system.

THERAPEUTIC SIGNIFICANCE:
The exploration of Killer cell immunoglobulin-like receptor 2DS4's function in the immune system is a promising area for drug discovery. Given its role in modulating NK cell activity without inhibition, targeting KIR2DS4 could lead to innovative treatments that enhance the body's natural defense mechanisms against various diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.